Company insight
Bringing clarity to ophthalmics
Terumo launches its Terumo Injection Filter Needle, a first step of the INFINO™ – Development Programme, to extend the choice for hypodermic and intravitreal injections.
of the Terumo Injection Filter Needle, a first step of the INFINO™ - Development Programme. Indicated for hypodermic as well as for intravitreal injections, the Injection Filter Needle features an integrated polyamide 5 micrometer mesh filter to prevent particles from being injected.
O
Precision filtration for critical injections
Developed to extend the options for its partners in the pharmaceutical industry working towards greater safety in injected drug delivery, particularly with respect to injection into sensitive areas such as to the vitreous humour in the eye, the Terumo Injection Filter Needle features an extra thin-walled cannula. Terumo K-Pack needles 30G with an analogous ETW-cannula show more than four times higher flow rate compared to regular wall alternatives*.
A specific hub design – in shape and material – has been developed with the aim to enhance connection between needle and syringe. This hub carries a polymer filter, intended to retain particulate matters of intrinsic or extrinsic origin. The new product is supplied in soft-blister packaging for aseptic presentation.
Stringent and extensive performance testing Working closely with its customers, Terumo ensures that all the verification and validation activities required for the specific intended use – hypodermic and intravitreal injections – are in place. In doing so, its customers can leverage the benefits of the Terumo Injection Filter Needle to offer a complete solution for
Terumo’s Injection Filter Needle is designed for hypodermic and intravitreal injections with an integrated 5μm filter to prevent particle injection
such applications, when combined with a similarly validated syringe. “With the number of intravitreal injections increasing due to the growing prevalence of eye diseases such as neovascular age-related macular degeneration, diabetic retinopathy and diabetic macular oedema, and retinal vein occlusion1
, Terumo engaged its
capabilities to provide an alternative to the less-than-ideal but commonplace use of ‘off label’ hypodermic needles for intravitreal injection, a practice evidenced by recent field safety notices,” said Marco Chiado Piat, president of pharmaceutical solutions division at Terumo Europe N.V..
Thomas Isaac, global product manager, pharmaceutical solutions division, Terumo Europe N.V. also added “The potential presence of particulates following intravitreal procedures may be linked with complications including impaired vision, sustained increases in intraocular pressure, and endophthalmitis, a rare but severe condition that can lead to sight loss.”2, 3 The Terumo Injection Filter Needle is compliant with the ISO 80369-7 standard and has been subject to stringent and extensive testing to determine biological
World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net
properties and filtration performance and to meet sterility requirements. The new product is the first marketed product example from the INFINO Development project.
“INFINO is a trademark filed by
Terumo Europe N.V. for medical devices to be developed with specific features. All brand names are trademarks or registered trademarks owned by Terumo Corporation, its affiliates, or unrelated third parties.
About Terumo Pharmaceutical Solutions Division Terumo Pharmaceutical Solutions develops patient-oriented parenteral delivery solutions for therapeutic performance and safety. Globally trusted for quality and precision, Terumo offers pharmaceutical and medical device manufacturers around the world, comprehensive product design and development services as well as a portfolio of injection, infusion, primary packaging, and CDMO solutions. ●
*Data on file. References available on request.
www.terumopharmaceutical
solutions.com
25
n January 22nd 2025 – Terumo Corporation (TSE: 4543) announced the global launch
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58
